The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
Global hepatitis C elimination: an investment framework
Lancet Gastroenterol Hepatoldoi: 10.1016/S2468-1253(20)30010-8. Online ahead of print.
Alisa Pedrana1, Jessica Howell2, Nick Scott3, Sophia Schroeder3, Christian Kuschel4, Jeffrey V Lazarus5, Rifat Atun6, Ricardo Baptista-Leite7, Ellen 't Hoen8, Sharon J Hutchinson9, Lisa Aufegger10, Raquel Peck11, Annette H Sohn12, Tracy Swan13, Mark Thursz14, Olufunmilayo Lesi15, Manik Sharma16, John Thwaites17, David P Wilson3, Margaret Hellard18
Author information
1Disease Elimination Program, Burnet Institute, Melbourne, VIC, Australia; School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia. Electronic address: alisa.pedrana@burnet.edu.au.
2Disease Elimination Program, Burnet Institute, Melbourne, VIC, Australia; Department of Medicine, University of Melbourne, Melbourne, VIC, Australia; Department of Gastroenterology, St Vincent's Hospital Melbourne, VIC, Australia.
3Disease Elimination Program, Burnet Institute, Melbourne, VIC, Australia; School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia.
4Disease Elimination Program, Burnet Institute, Melbourne, VIC, Australia.
5Barcelona Institute for Global Health, Hospital Clínic, University of Barcelona, Barcelona, Spain.
6Department of Global Health and Population, Harvard T H Chan School of Public Health, Harvard University, Boston, MA, USA.
7Institute of Health Sciences, Universidade Catolica Portuguesa, Lisbon, Portugal; Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, Netherlands.
8Global Health Unit, University Medical Centre Groningen, Groningen, Netherlands; Medicines Law & Policy, Amsterdam, Netherlands.
9School of Health and Life Sciences, Glasgow Caledonian University, Glasgow, UK; Health Protection Scotland, Glasgow, UK.
10Centre for Health Policy, Imperial College London, London, UK.
11World Hepatitis Alliance, Imperial College London, London, UK.
12TREAT Asia/amfAR-Foundation for AIDS Research Bangkok, Bangkok, Thailand.
13Independent consultant, Barcelona, Spain.
14Department of Hepatology, Imperial College London, London, UK.
15College of Medicine, University of Lagos, Lagos, Nigeria.
16Department of Gastroenterology and Hepatology, Hamad Medical Corporation, Doha, Qatar.
17Monash Sustainable Development Institute and ClimateWorks Australia, Melbourne, VIC, Australia.
18Disease Elimination Program, Burnet Institute, Melbourne, VIC, Australia; School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia; Doherty Institute and Melbourne School of Population and Global Health, University of Melbourne, Melbourne, VIC, Australia; Department of Infectious Diseases, The Alfred and Monash University, Melbourne, VIC, Australia.
Abstract
WHO has set global targets for the elimination of hepatitis B and hepatitis C as a public health threat by 2030. However, investment in elimination programmes remains low. To help drive political commitment and catalyse domestic and international financing, we have developed a global investment framework for the elimination of hepatitis B and hepatitis C. The global investment framework presented in this Health Policy paper outlines national and international activities that will enable reductions in hepatitis C incidence and mortality, and identifies potential sources of funding and tools to help countries build the economic case for investing in national elimination activities. The goal of this framework is to provide a way for countries, particularly those with minimal resources, to gain the substantial economic benefit and cost savings that come from investing in hepatitis C elimination.